Linezolid for the Treatment of Multidrug‐Resistant, Gram‐Positive Infections: Experience from a Compassionate‐Use Program
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Linezolid was provided for treatment of multidrug-resistant, gram-positive infections through a compassionate-use program. Patients (n=796) received 600 mg of linezolid intravenously or orally every 12 h (828 treatment courses). Bacteremia was present in 46% of infections, endocarditis was present in 10.6%, and line-related infections were present in 31.1%. Other infections included intraabdominal infections (15.1%), complicated skin and skin-structure infections (13.3%), and osteomyelitis (10.7%). Causative pathogens included vancomycin-resistant enterococci (66.3%) and methicillin-resistant staphylococci (22.1%). Clinical intent-to-treat (ITT) outcomes in the evaluable population were as follows: cure, 73.3%; failure, 6.8%; and indeterminate, 19.9%. Microbiological ITT outcomes in evaluable patients were as follows: cure, 82.4%; failure, 14.1%; and indeterminate, 3.5%. At the test of cure assessment, the clinical cure and microbiological success rates were 91.5% and 85.8%, respectively. The most common adverse events possibly related to linezolid use were gastrointestinal disturbances (9.8% of cases), thrombocytopenia (7.4% of cases), decreased hemoglobin/hematocrit levels (4.1% of cases), and cutaneous reactions (4.0% of cases). Linezolid provided high rates of clinical cure and microbiological success in this complicated patient population, with very good overall tolerance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Birmingham et al 202 reported cure in 17 of 22 courses of therapy (77%) for E faecium IE.”
Citations
Cites
Emergence of Vancomycin Resistance in Staphylococcus aureus
Smith, T. L., Pearson, M. L., Wilcox, K. R., Cruz, C., Lancaster, M. V., Robinson-Dunn, B., Tenover, F. C., Zervos, M. J., Band, J. D., White, E., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400701 · Cited by 1,088
Linezolid resistance in a clinical isolate of Staphylococcus aureus
Tsiodras, S., Gold, H. S., Sakoulas, G., Eliopoulos, G. M., Wennersten, C., Venkataraman, L., Moellering, R. C., & Ferraro, M. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05410-1 · Cited by 1,033
Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid
Gonzales, R. D., Schreckenberger, P. C., Graham, M. B., Kelkar, S., DenBesten, K., & Quinn, J. P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04376-2 · Cited by 542
Stevens, D. L., Herr, D., Lampiris, H., Hunt, J. L., Batts, D. H., Hafkin, B., & the Linezolid MRSA Study Group (2002) · Clinical Infectious Diseases · doi:10.1086/340353 · Cited by 506
Self-citationIn vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents
Zurenko, G. E., Yagi, B. H., Schaadt, R. D., Allison, J. W., Kilburn, J. O., Glickman, S. E., Hutchinson, D. K., Barbachyn, M. R., & Brickner, S. J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.4.839 · Cited by 461
Hematologic Effects of Linezolid: Summary of Clinical Experience
Gerson, S. L., Kaplan, S. L., Bruss, J. B., Le, V., Arellano, F. M., Hafkin, B., & Kuter, D. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2723-2726.2002 · Cited by 443
Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions
Shinabarger, D. L., Marotti, K. R., Murray, R. W., Lin, A. H., Melchior, E. P., Swaney, S. M., Dunyak, D. S., Demyan, W. F., & Buysse, J. M. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2132 · Cited by 384
Vancomycin Resistance in Staphylococci
Srinivasan, A., Dick, J. D., & Perl, T. M. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.3.430-438.2002 · Cited by 285
Thrombocytopenia Associated with Linezolid Therapy
Attassi, K., Hershberger, E., Alam, R., & Zervos, M. J. (2002) · Clinical Infectious Diseases · doi:10.1086/338403 · Cited by 259
Slatter, J. G., Stalker, D. J., Feenstra, K. L., Welshman, I. R., BRUSS, J. B., Sams, J. P., Johnson, M. G., Sanders, P., Hauer, M. J., Fagerness, P. E., et al. (2001) · PubMed · Cited by 248
Research works printed but not linked: 8
- 2002, MMWR Morb Mortal Wkly Rep, 51, 565
- Stalker DJ, 1997, DC: American Society for Microbiology, 23
- Stalker DJ, Wajszczuk CP, Batts DH. Linezolid safety, tolerance and pharmacokinetics following oral dosing twice daily for 14.5 days [abstract A115]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997:23.
- Wynalda MA, 2000, Drug Metab Dispos, 28, 1014
- Slatter JG, 2001, Drug Metab Dispos, 29, 1136
- Dresser LD, Birmingham MC, Karchmer AW, Rayner CR, Falvin SM, Schentag JJ. Results of treating infective endocarditis with linezolid [abstract 2239]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000:5.
- Zurenko GE, Todd WM, Hafkin B, etal Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid [abstract 848]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1997:118.
- Forrest A, Rayner CR, Meagher AK, Birmingham MC, Schentag JJ. Pharmacostatistical modelling of hematologic effects of linezolid (L) in seriously-ill patients (pts) [abstract 283]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000:5.
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Lew, D. P., & Waldvogel, F. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16727-5 · Cited by 1,883
Antibiotics and Bacterial Resistance in the 21st Century
Fair, R. J., & Tor, Y. (2014) · Perspectives in Medicinal Chemistry · doi:10.4137/pmc.s14459 · Cited by 1,955
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707
Moise-Broder, P. A., Forrest, A., Birmingham, M. C., & Schentag, J. J. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443130-00005 · Cited by 757
Self-citationThe Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection
Mazuski, J. E., Tessier, J. M., May, A. K., Sawyer, R. G., Nadler, E. P., Rosengart, M. R., Chang, P. K., O'Neill, P. J., Mollen, K. P., Huston, J. M., et al. (2017) · Surgical Infections · doi:10.1089/sur.2016.261 · Cited by 573
Gould, F. K., Denning, D. W., Elliott, T. S. J., Foweraker, J., Perry, J. D., Prendergast, B. D., Sandoe, J. A. T., Spry, M. J., & Watkin, R. W. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr450 · Cited by 593
Craig, W. A. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00065-5 · Cited by 556
Crank, C., & O'Driscoll, T. (2015) · Infection and Drug Resistance · doi:10.2147/idr.s54125 · Cited by 505
Linezolid: a review of its properties, function, and use in critical care
Hashemian, S. M., Farhadi, T., & Ganjparvar, M. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s164515 · Cited by 459
Antituberculosis drugs: Ten years of research
Janin, Y. L. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.01.030 · Cited by 485
Systemic Antibiotic Therapy for Chronic Osteomyelitis in Adults
Spellberg, B., & Lipsky, B. A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir842 · Cited by 470
Clinical Management of Staphylococcus aureus Bacteremia: A Review
Holland, T. L., Arnold, C., & Fowler, V. G. (2014) · JAMA · doi:10.1001/jama.2014.9743 · Cited by 449
Linezolid versus Vancomycin in Treatment of Complicated Skin and Soft Tissue Infections
Weigelt, J., Itani, K., Stevens, D., Lau, W., Dryden, M., & Knirsch, C. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.6.2260-2266.2005 · Cited by 457
Gemmell, C. G., Edwards, D. I., Fraise, A. P., Gould, F. K., Ridgway, G. L., & Warren, R. E. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl017 · Cited by 439
Management of infective endocarditis: challenges and perspectives
Thuny, F., Grisoli, D., Collart, F., Habib, G., & Raoult, D. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60755-1 · Cited by 437
Oxazolidinones: activity, mode of action, and mechanism of resistance
Bozdogan, B., & Appelbaum, P. C. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2003.11.003 · Cited by 403
Lazzarini, L., Mader, J. T., & Calhoun, J. H. (2004) · The Journal of Bone & Joint Surgery · doi:10.2106/00004623-200410000-00028 · Cited by 400
Management of multidrug-resistant enterococcal infections
Arias, C. A., Contreras, G. A., & Murray, B. E. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03214.x · Cited by 388
Hossain, T. J. (2024) · European Journal of Microbiology and Immunology · doi:10.1556/1886.2024.00035 · Cited by 392
Linezolid-Induced Inhibition of Mitochondrial Protein Synthesis
De Vriese, A. S., Van Coster, R., Smet, J., Seneca, S., Lovering, A., Van Haute, L. L., Vanopdenbosch, L. J., Martin, J.-J., Ceuterick-de Groote, C., Vandecasteele, S., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/501356 · Cited by 323
Rayner, C. R., Forrest, A., Meagher, A. K., Birmingham, M. C., & Schentag, J. J. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342150-00007 · Cited by 306
Self-citationEmergence and management of drug-resistant enterococcal infections
Arias, C. A., & Murray, B. E. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.5.637 · Cited by 294
Bender, J. K., Cattoir, V., Hegstad, K., Sadowy, E., Coque, T. M., Westh, H., Hammerum, A. M., Schaffer, K., Burns, K., Murchan, S., et al. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.10.002 · Cited by 281
Enterococcal Infection—Treatment and Antibiotic Resistance
Kristich, C. J., Rice, L. B., & Arias, C. A. (2014) · Europe PMC (PubMed Central) · Cited by 274
The oxazolidinones: past, present, and future
Shaw, K. J., & Barbachyn, M. R. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06330.x · Cited by 259
Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs
Broyles, A. D., Banerji, A., Barmettler, S., Biggs, C. M., Blumenthal, K., Brennan, P. J., Breslow, R. G., Brockow, K., Buchheit, K. M., Cahill, K. N., et al. (2020) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2020.08.006 · Cited by 235
Peripheral neuropathy associated with prolonged use of linezolid
Bressler, A. M., Zimmer, S. M., Gilmore, J. L., & Somani, J. (2004) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(04)01109-0 · Cited by 246
Bone and Joint Infections in Children
Gutierrez, K. (2005) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2005.02.005 · Cited by 237
Linezolid: a review of safety and tolerability
Vinh, D. C., & Rubinstein, E. (2009) · Journal of Infection · doi:10.1016/s0163-4453(09)60009-8 · Cited by 213
Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conference
Sartelli, M., Catena, F., Abu-Zidan, F. M., Ansaloni, L., Biffl, W. L., Boermeester, M. A., Ceresoli, M., Chiara, O., Coccolini, F., De Waele, J. J., et al. (2017) · World Journal of Emergency Surgery · doi:10.1186/s13017-017-0132-7 · Cited by 199
Safety and tolerability of linezolid
French, G. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg253 · Cited by 203
Antimicrobial-resistant CC17 Enterococcus faecium: The past, the present and the future
Lee, T., Pang, S., Abraham, S., & Coombs, G. W. (2019) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2018.08.016 · Cited by 190
Microbiological Spectrum and Antibiotic Sensitivity in Endophthalmitis
Gentile, R. C., Shukla, S., Shah, M., Ritterband, D. C., Engelbert, M., Davis, A., & Hu, D.-N. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.02.001 · Cited by 196
Calhoun, J. H., & Manring, M. M. (2005) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2005.07.009 · Cited by 175
Shorr, A. F., Kunkel, M. J., & Kollef, M. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki355 · Cited by 198
Linezolid‐Associated Peripheral and Optic Neuropathy, Lactic Acidosis, and Serotonin Syndrome
Narita, M., Tsuji, B. T., & Yu, V. L. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.8.1189 · Cited by 190
Enterococcal Disease, Epidemiology, and Implications for Treatment
Higuita, N. I. A., & Huycke, M. M. (2014) · Europe PMC (PubMed Central) · Cited by 214
Rubinstein, E., Isturiz, R., Standiford, H. C., Smith, L. G., Oliphant, T. H., Cammarata, S., Hafkin, B., Le, V., & Remington, J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.6.1824-1831.2003 · Cited by 177
Endocarditis and Intravascular Infections
Saiman, L. (2008) · Principles and Practice of Pediatric Infectious Disease · doi:10.1016/b978-0-7020-3468-8.50045-6 · Cited by 177
Staphylococcus aureus Bloodstream Infections: Definitions and Treatment
Corey, G. R. (2009) · Clinical Infectious Diseases · doi:10.1086/598186 · Cited by 166
Falagas, M. E. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl219 · Cited by 167
Antibiotic Adverse Reactions and Drug Interactions
Granowitz, E. V., & Brown, R. B. (2008) · Critical Care Clinics · doi:10.1016/j.ccc.2007.12.011 · Cited by 160
Population Pharmacokinetics of Linezolid in Patients Treated in a Compassionate-Use Program
Meagher, A. K., Forrest, A., Rayner, C. R., Birmingham, M. C., & Schentag, J. J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.2.548-553.2003 · Cited by 154
Self-citationRivera, A. M., & Boucher, H. W. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2011.0514 · Cited by 153
Antibiotics that target protein synthesis
McCoy, L. S., Xie, Y., & Tor, Y. (2010) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.60 · Cited by 174
A review of linezolid: the first oxazolidinone antibiotic
Stevens, D. L., Dotter, B., & Madaras‐Kelly, K. (2004) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2.1.51 · Cited by 152
Bishop, E. J., Melvani, S., Howden, B. P., Charles, P. G. P., & Grayson, M. L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1599-1602.2006 · Cited by 146
Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)—a report of ten cases
von der Lippe, B., Sandven, P., & Brubakk, O. (2005) · Journal of Infection · doi:10.1016/j.jinf.2005.04.007 · Cited by 142
Elliott, T., Foweraker, J. E., Gould, F. K., Perry, J. D., & Sandoe, J. A. T. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh474 · Cited by 149
Takahashi, Y., Takesue, Y., Nakajima, K., Ichiki, K., Tsuchida, T., Tatsumi, S., Ishihara, M., Ikeuchi, H., & Uchino, M. (2010) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-010-0182-1 · Cited by 136
Evolving trends in infective endocarditis
Hill, E. E., Herijgers, P., Herregods, M., & Peetermans, W. E. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01289.x · Cited by 131
Clinical Population Pharmacokinetics and Toxicodynamics of Linezolid
Boak, L. M., Rayner, C. R., Grayson, M. L., Paterson, D. L., Spelman, D., Khumra, S., Capitano, B., Forrest, A., Li, J., Nation, R. L., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01885-13 · Cited by 130
Self-citationDesign, Synthesis, and Biological Evaluation of New Cinnamic Derivatives as Antituberculosis Agents
De, P., Yoya, G. K., Constant, P., Bedos‐Belval, F., Duran, H., Saffon‐Merceron, N., Daffé, M., & Baltas, M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101510d · Cited by 128
Drug-Related Mitochondrial Optic Neuropathies
Wang, M. Y., & Sadun, A. A. (2013) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0b013e3182901969 · Cited by 124
Jones, R. N., Fritsche, T. R., Sader, H. S., & Ross, J. E. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.06.004 · Cited by 129
Linezolid-associated toxic optic neuropathy
Rucker, J. C., Hamilton, S. R., Bardenstein, D. S., Isada, C. M., & Lee, M. (2006) · Neurology · doi:10.1212/01.wnl.0000201313.24970.b8 · Cited by 118
Linezolid in the Treatment of Osteomyelitis: Results of Compassionate Use Experience
Rayner, C. R., Baddour, L. M., Birmingham, M. C., Norden, C. W., Meagher, A. K., & Schentag, J. J. (2004) · Infection · doi:10.1007/s15010-004-3029-9 · Cited by 117
Self-citationEmerging Options for Treatment of Invasive, Multidrug‐Resistant Staphylococcus aureus Infections
Drew, R. H. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.2.227 · Cited by 123
Cepeda, J. A., Whitehouse, T., Cooper, B., Hails, J., Jones, K., Kwaku, F., Taylor, L., Hayman, S., Shaw, S., Kibbler, C., et al. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh048 · Cited by 114
Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms
Sy, C.-L., Chen, P., Cheng, C.-W., Huang, L.-J., Wang, C.-H., Chang, T., Chang, Y., Chang, C.-J., Hii, I.-M., Hsu, Y., et al. (2022) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2022.02.001 · Cited by 113
New antimicrobial agents as therapy for resistant gram-positive cocci
Lentino, J. R., Narita, M., & Yu, V. L. (2007) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-007-0389-y · Cited by 121
Dahl, A., Rasmussen, R. V., Bundgaard, H., Hassager, C., Bruun, L. E., Lauridsen, T. K., Moser, C., Sogaard, P., Arpi, M., & Bruun, N. E. (2013) · Circulation · doi:10.1161/circulationaha.112.001170 · Cited by 108
Tsuji, Y., Holford, N. H. G., Kasai, H., Ogami, C., Heo, Y., Higashi, Y., Mizoguchi, A., To, H., & Yamamoto, Y. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13262 · Cited by 106
Xia, G., Liu, Y., Tian, M., Gao, P., Bao, Z., Bai, X., Yu, X., Lang, X., Hu, S., & Chen, X. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb00479f · Cited by 100
Beibei, L., Yun, C., Mengli, C., Nan, B., Xuhong, Y., & Wang, R. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.09.013 · Cited by 97
Tsuji, Y., Mizoguchi, A., Sadoh, S., Hiraki, Y., Matsumoto, K., Morita, K., Kobayashi, T., Kamimura, H., & Karube, Y. (2010) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-010-0080-6 · Cited by 96
A potential role for daptomycin in enterococcal infections: what is the evidence?
Cantón, R., Ruíz-Garbajosa, P., Chaves, R. L., & Johnson, A. P. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq087 · Cited by 91
Whang, D. W., Miller, L. G., Partain, N. M., & McKinnell, J. A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00714-13 · Cited by 91
Senneville, É., Legout, L., Valette, M., Yazdanpanah, Y., Giraud, F., Beltrand, E., Obert, G., Dubreuil, L. J., Migаud, H., & Mouton, Y. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh409 · Cited by 91
Linezolid-Associated Peripheral Neuropathy
Rho, J. P., Sia, I. G., Crum, B. A., Dekutoski, M. B., & Trousdale, R. T. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.7.927 · Cited by 90
Palavecino, E. L. (2007) · Methods in molecular biology · doi:10.1007/978-1-59745-468-1_1 · Cited by 107
Lortholary, O., Lefort, A., Tod, M. M., Chomat, A. M., Darras-Joly, C., & Cordonnier, C. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70228-7 · Cited by 89
Combatting resistant enterococcal infections: a pharmacotherapy review
Mercuro, N. J., Davis, S. L., Zervos, M., & Herc, E. S. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1479397 · Cited by 98
Linezolid-induced optic neuropathy: a mitochondrial disorder?
Javaheri, M., Khurana, R. N., O’Hearn, T. M., Lai, M. M.-S., & Sadun, A. A. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.102541 · Cited by 88
Clinical update on linezolid in the treatment of Gram-positive bacterial infections
Gould, K. (2012) · Infection and Drug Resistance · doi:10.2147/idr.s25890 · Cited by 98
Pharmacokinetics and Pharmacodynamics of Linezolid in Obese Patients with Cellulitis
Stein, G. E., Schooley, S. L., Peloquin, C. A., Kak, V., Havlichek, D. H., Citron, D. M., Tyrrell, K. L., & Goldstein, E. J. C. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e484 · Cited by 87
Pharmacological Issues of Linezolid: An Updated Critical Review
Paolo, A. D., Malacarne, P., Guidotti, E., Danesi, R., & Tacca, M. D. (2010) · Clinical Pharmacokinetics · doi:10.2165/11319960-000000000-00000 · Cited by 85
Smith, P. F., Birmingham, M. C., Noskin, G. A., Meagher, A. K., Forrest, A., Rayner, C. R., & Schentag, J. J. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg211 · Cited by 84
Self-citationDrug-induced thrombocytopenia in critically ill patients
Priziola, J. L., Smythe, M. A., & Dager, W. E. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181de0b88 · Cited by 83
Endocarditis Due to Vancomycin-Resistant Enterococci: Case Report and Review of the Literature
Stevens, M., & Edmond, M. B. (2005) · Clinical Infectious Diseases · doi:10.1086/444459 · Cited by 82
Safety and tolerability of linezolid in children
Saiman, L. M., Goldfarb, J., KAPLAN, S. A., Wible, K. L., EDGE-PADBURY, B., NABERHUIS-STEHOUWER, S., & BRUSS, J. B. (2003) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000087022.58089.d8 · Cited by 79
Severe bilateral optic neuritis associated with prolonged linezolid therapy
Frippiat, F., Bergiers, C., Michel, C., Dujardin, J.-P., & Derue, G. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh199 · Cited by 77
Yang, J. S., Kim, K. J., Choi, H., & Lee, S. H. (2018) · Annals of Laboratory Medicine · doi:10.3343/alm.2018.38.6.563 · Cited by 76
Nasraway, S. A., Shorr, A. F., Kuter, D. J., O'Grady, N., Le, V. H., & Cammarata, S. (2003) · Clinical Infectious Diseases · doi:10.1086/379327 · Cited by 76
Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children
Kaplan, S. L., Afghani, B., López, P., Wu, E., Fleishaker, D. L., EDGE-PADBURY, B., NABERHUIS-STEHOUWER, S., & BRUSS, J. B. (2003) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000087020.75886.93 · Cited by 75
New Drugs for Tuberculosis: Current Status and Future Prospects
O'Brien, R. J., & Spigelman, M. (2005) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2005.02.013 · Cited by 75
Willekens, R., Puig‐Asensio, M., Ruíz-Camps, I., Larrosa, N., González‐López, J. J., Rodríguez-Pardo, D., Fernández‐Hidalgo, N., Pigrau, C., & Almirante, B. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy916 · Cited by 73
Structural basis for context-specific inhibition of translation by oxazolidinone antibiotics
Tsai, K., Stojković, V., Lee, D. J., Young, I. D., Szal, T., Klepacki, D., Vázquez‐Laslop, N., Mankin, A. S., Fraser, J. S., & Fujimori, D. G. (2022) · Nature Structural & Molecular Biology · doi:10.1038/s41594-022-00723-9 · Cited by 74
Treatment of Enterococcus faecalis Infective Endocarditis: A Continuing Challenge
Hidalgo, L. H., Fernández-Rubio, B., Márquez, R. L., López-Cortés, L. E., Gil-Navarro, M. V., & de Alarcón, A. (2023) · Antibiotics · doi:10.3390/antibiotics12040704 · Cited by 81
Mycobacterium tuberculosis Mutations Associated with Reduced Susceptibility to Linezolid
Zhang, S., Chen, J., Cui, P., Shi, W., Shi, X., Niu, H., Chan, D. P. C., Yew, W. W., Zhang, W., & Zhang, Y. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02941-15 · Cited by 72
Eckmann, C., Dryden, M., Montravers, P., Kozlov, R. S., & Sganga, G. (2011) · European journal of medical research · doi:10.1186/2047-783x-16-3-115 · Cited by 81
Jones, R. N., Ross, J. E., Fritsche, T. R., & Sader, H. S. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki437 · Cited by 74
Crank, C. W., Scheetz, M. H., Brielmaier, B. D., Rose, W. E., Patel, G. P., Ritchie, D. J., & Segreti, J. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.09.008 · Cited by 69
Clinical efficacy and tolerability of linezolid in pediatric patients: A systematic review
Chiappini, E., Conti, C., Galli, L., & de Martino, M. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.01.019 · Cited by 69
Erlandson, K. M., Sun, J., Iwen, P. C., & Rupp, M. E. (2007) · Clinical Infectious Diseases · doi:10.1086/523588 · Cited by 69
Risk Factors for Thrombocytopenia in Adult Chinese Patients Receiving Linezolid Therapy
Chen, C., Guo, D., Cao, X., Cai, Y., Xu, Y., Zhu, M., & Ma, L. (2012) · Current Therapeutic Research · doi:10.1016/j.curtheres.2012.07.002 · Cited by 68
Sparo, M. D., Delpech, G., & Allende, N. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03073 · Cited by 78
Molecular Basis of Non-β-Lactam Antibiotics Resistance in Staphylococcus aureus
Lade, H. S., Joo, H., & Kim, J. (2022) · Antibiotics · doi:10.3390/antibiotics11101378 · Cited by 74
Enterococcus faecalisinfective endocarditis: focus on clinical aspects
Dahl, A., & Bruun, N. E. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2013.832482 · Cited by 80
Metadata
- Authors
- Birmingham, M. C., Rayner, C. R., Meagher, A. K., Flavin, S. M., Batts, D. H., & Schentag, J. J.
- Affiliations
- University at Buffalo, State University of New York (US)
- Kalamazoo Public Library (US)
- Corresponding author
- Schentag, Jerome J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-01-15
- Volume
- 36
- Issue
- 2
- Pages
- 159-168
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2153039659
- Semantic Scholar
- 884899ebe7caae27908d4715f8dc57cf1db6c0c1
- Cited by
- 428
- References
- 25
- Citations by year
- 2026: 6 · 2025: 15 · 2024: 8 · 2023: 14 · 2022: 7 · 2021: 9 · 2020: 18 · 2019: 12 · 2018: 17 · 2017: 14 · 2016: 13 · 2015: 21 · 2014: 19 · 2013: 19 · 2012: 13
- FWCI
- 21.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- linezolid, compassionate use program, vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, bacteremia, endocarditis, osteomyelitis, complicated skin and skin structure infections, intra-abdominal infection, clinical cure, adverse events, drug tolerability
- MeSH terms
- Linezolid, Acetamides, Adolescent, Adult, Aged, Anti-Infective Agents, Drug Interactions, Female, Humans, Male, Middle Aged, Treatment Outcome, Gram-Positive Bacterial Infections, Drug Resistance, Multiple, Oxazolidinones, Drug Resistance, Bacterial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.